On February 6, 2026, the FDA took the unusual step of naming Hims & Hers Health specifically in an enforcement announcement targeting compounded GLP-1 marketing. The agency warned that it would take action against entities engaged in the "manufacture, distribution, or marketing of unapproved compounded GLP-1 products" — and singled out Hims as an example.

Five months later, here's where things stand.

What the FDA Actually Said

The February announcement accused certain telehealth platforms — Hims prominently among them — of "misleading direct-to-consumer advertising and marketing" of compounded GLP-1 products. The FDA warned that failure to address violations could result in "legal action without further notice, including seizure and injunction."

This was part of a broader escalation that included the launch of TrumpRx (February 5, 2026), which positioned itself as the government's endorsed pathway to affordable brand GLP-1 medications — in implicit contrast to the compounding market.

Hims's Response and Current Status

Following the FDA announcement, Hims moved quickly to adjust its GLP-1 offerings. The company has pivoted toward promoting FDA-approved brand medications alongside (or instead of) compounded alternatives, partnering with Novo Nordisk's distribution channels to offer brand Wegovy through its platform.

Hims remains a publicly traded company (NYSE: HIMS) with significant revenue dependent on GLP-1 products. The stock experienced notable volatility around the February announcement, and the company has been transparent in SEC filings about regulatory risk to its GLP-1 business.

For Current Hims Patients
If you're currently receiving GLP-1 medication through Hims, your prescription and supply are not immediately affected. However, the product you receive may be transitioning from compounded to brand-name, and pricing may change accordingly. Contact Hims directly for current product and pricing information for your specific prescription.

The Broader Telehealth Pattern

Hims is the most prominent example of a broader pattern: large telehealth platforms that built GLP-1 businesses during the shortage era are now navigating the transition to a post-shortage regulatory environment. Some are pivoting to brand products. Others are restructuring their pharmacy relationships to work exclusively with 503A providers. A few have exited the GLP-1 market entirely.

For patients, the lesson is practical: don't assume any single platform's GLP-1 offering will remain unchanged indefinitely. The regulatory landscape is shifting monthly, and platforms are adapting in real time.

Alternatives for Former Hims Patients

If you've been displaced from Hims's GLP-1 program or are concerned about future disruption, multiple verified 503A compounding providers remain operational and accepting new patients. The transition is typically straightforward: your new provider will need your current dose, treatment history, and a new telehealth evaluation.

Find a Stable Alternative

Compare verified providers that have demonstrated regulatory stability through 2026.

Compare Alternatives →